An internal standard for the quantification of rivaroxaban
Rivaroxaban-d4 is intended for use as an internal standard for the quantification of rivaroxaban by GC- or LC-MS. Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.1 It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases. In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time. Formulations containing rivaroxaban have been used as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.2,3
1.Turpie, A.G.G.Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseasesArterioscler. Thromb. Vasc. Biol.27(6)1238-1247(2007) 2.Babilonia, K., and Trujillo, T.The role of prothrombin complex concentrates in reversal of target specific anticoagulantsThromb. J.12:8(2014) 3.Turpie, A.G.G.Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillationTher. Clin. Risk Manag.10197-205(2014)
动态评分
0.0